690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain

Abstract

Once-weekly Semaglutide (OWS) is available for the treatment of patients with T2D (PwT2D) in Spain since May 2019. We examined the effect of OWS in glycemic and weight management in a real-world setting in Spain. Adult PwT2D that were prescribed OWS in 4 Hospitals in Madrid-Spain were identified. Patients with OWS withdrawal were excluded. Change in HbA1c and weight at 6±3 months (full cohort) and at 12±3 months (subgroup) was analyzed separately in GLP-1-naive and GLP-1-experienced patients. Baseline data is shown in Table-1. Significant HbA1c and weight reductions were found in both groups (GLP-1 naive and GLP-1 experienced). It was significant for both, the 6±3 month and the 12±3 month cohorts (Table-1). Conclusions: OWS treatment showed significant HbA1c and weight reductions in a real world setting in Spain, in GLP-1 naive and GLP-1-experienced PwT2D. Disclosure J. J. Cardenas-salas: Other Relationship; Self; AstraZeneca, Lilly Diabetes, Mylan N. V., Novo Nordisk, Sanofi. R. Sierra: None. B. Luca: Other Relationship; Self; Almirall, S. A., Lilly Diabetes, Menarini Group, Mundipharma International, Novo Nordisk, Sanofi. B. Sanchez: None. N. Modrono: Other Relationship; Self; Menarini. C. Casado: None. N. M. Sanchez: None. E. Cruces: Other Relationship; Self; other. C. Vazquez: None.